Influenza Capabilities CSL Seqirus is the second largest influenza vaccine company with global manufacturing and a presence in over 20 countries, offering opportunities to sell in both seasonal and pandemic preparedness markets through existing capacity and distribution channels.

Public Health Collaboration Active partnerships with government health agencies and ongoing work on avian influenza and H5N1 vaccine development present opportunities to propose large-scale public sector collaborations, procurement programs, and stockpile readiness contracts.

Manufacturing Scale Significant manufacturing footprint in the US, UK, Germany, and Australia combined with a sizable workforce enables scalable supply agreements, risk-sharing manufacturing contracts, and faster time-to-market for vaccines and related biologics.

Adjuvanted and Cell-Based Focus on cell-based and adjuvanted seasonal influenza vaccines provides a pathway to upsell enhanced efficacy formulations, clinical study collaborations, and data-driven value propositions for payers and health systems.

Expansion Readiness Recent R&D and regulatory activity, plus leadership hires in manufacturing, signals potential for expanded product lines or contract manufacturing opportunities, especially for vaccine variants, antivenoms, and nationally significant vaccines.